Coverage of issues such as drug prices and insurance supply chains that impact people’s ability to access medicine and therapies.
More
The art of the deal: what are Trump’s pharma announcements really worth?
This content was published on
Big Pharma announced a series of groundbreaking agreements with the White House in 2025. But how much of it is just for show?
The art of the deal: what are Trump’s pharma announcements really worth?
This content was published on
Big Pharma announced a series of groundbreaking agreements with the White House in 2025. But how much of it is just for show?
This content was published on
Despite success with injectable drugs pharma companies are investing heavily in tablets, long considered the holy grail of obesity medicine.
Swiss drugmakers face mixed fortunes amid Trump’s tariff upheaval
This content was published on
Pharma giants may escape the worst of the import tariffs threatened by the US. But Switzerland’s smaller developers face a more uncertain future.
How a clash with Roche exposed cracks in Swiss drug pricing system
This content was published on
Switzerland’s new process to speed up patient access to the latest drugs hit its first major hurdle in a clash with Roche.
Potential US tariff exemption for Swiss pharma is not necessarily a boon
This content was published on
Donald Trump is pressuring the pharma industry with tariffs. But experts say that tariffs will have less impact on the industry than pricing.
When sperm crosses borders, national safeguards fall short
This content was published on
The sperm of a Danish donor carried a cancer-causing genetic mutation that led to the deaths of children. Switzerland’s strict regulations make scenarios of this scale unlikely.
How private equity oversees the ethics of drug research
This content was published on
Many drug trials are vetted by companies with ties to the drugmakers, raising concerns about conflicts of interest and patient safety.
When diagnosing a disease does more harm than good
This content was published on
Switzerland has the highest number of MRI scanners per person in Europe. But more screening doesn’t always lead to better health outcomes.
Global concern over measles is rising. Should Switzerland worry?
This content was published on
Measles is making a global comeback. In Switzerland, a crisis is unlikely – but authorities warn a strong vaccination rate remains crucial.
Swiss regulator and media clash over weight-loss drugs
This content was published on
Swissmedic has taken legal action against media for alleged unauthorised advertising of weight-loss drugs. Swiss media say this is censorship.
Medicines regulators weigh hope and hype with new Alzheimer’s drugs
This content was published on
Swissmedic is expected to decide on the approval of the first new drug for Alzheimer’s disease in two decades. The decision won’t be easy.
This content was published on
Sales of counterfeit drugs are booming around the world, putting thousands of lives at risk. Why is it so hard to stem the tide of fake medicine?
US trade deal forces reckoning for Swiss pharma powerhouse
This content was published on
Swiss pharma made massive investment promises to the US that are fueling anxiety about the industry’s future in Switzerland.
Swiss drugmakers face mixed fortunes amid Trump’s tariff upheaval
This content was published on
Pharma giants may escape the worst of the import tariffs threatened by the US. But Switzerland’s smaller developers face a more uncertain future.
This content was published on
Ypsomed CEO explains why US tariffs are not a worry and why he sees more growth from diabetes and obesity treatments such as Ozempic.
Potential US tariff exemption for Swiss pharma is not necessarily a boon
This content was published on
Donald Trump is pressuring the pharma industry with tariffs. But experts say that tariffs will have less impact on the industry than pricing.
How US tariffs could disrupt the generic drugs supply chain
This content was published on
US tariffs on generics could raise drug prices and accentuate shortages. That’s not what US President Donald Trump had in mind.
Sandoz board chair ‘convinced that common sense will ultimately prevail’ on US pharma tariffs
This content was published on
In an exclusive interview with Swissinfo, Sandoz chair Gilbert Ghostine says he remains optimistic despite looming tariff hikes.
The art of the deal: what are Trump’s pharma announcements really worth?
This content was published on
Big Pharma announced a series of groundbreaking agreements with the White House in 2025. But how much of it is just for show?
When sperm crosses borders, national safeguards fall short
This content was published on
The sperm of a Danish donor carried a cancer-causing genetic mutation that led to the deaths of children. Switzerland’s strict regulations make scenarios of this scale unlikely.
How Switzerland became liberal on abortion – without noticing
This content was published on
From 2027 Swiss health insurers will cover the full cost of abortions. The change passed through parliament almost unnoticed.
Swiss drugmakers face mixed fortunes amid Trump’s tariff upheaval
This content was published on
Pharma giants may escape the worst of the import tariffs threatened by the US. But Switzerland’s smaller developers face a more uncertain future.
When diagnosing a disease does more harm than good
This content was published on
Switzerland has the highest number of MRI scanners per person in Europe. But more screening doesn’t always lead to better health outcomes.
Could a Danish‑style sperm donor scandal happen in Switzerland?
This content was published on
A sperm donor in Denmark carrying a cancer‑causing gene had almost 200 children… Could something like that happen in Switzerland?
This content was published on
In episode 6 of this season’s Swiss Connection science podcast, we look at the role of relationships and perceptions in longevity.
When sperm crosses borders, national safeguards fall short
This content was published on
The sperm of a Danish donor carried a cancer-causing genetic mutation that led to the deaths of children. Switzerland’s strict regulations make scenarios of this scale unlikely.
Science podcast: the story behind the ‘longevity pill’ rapamycin
This content was published on
In episode 5 of this season’s Swiss Connection science podcast, we talk about the discovery of TOR and its potential for longevity.
This content was published on
Medical experts now use artificial intelligence to help them diagnose and monitor diseases. But does this mean AI will replace doctors?
From London to Lausanne: how Isomorphic Labs is rewriting drug discovery
This content was published on
Google DeepMind spin-off Isomorphic Labs is expanding in Switzerland to achieve its ambitious goal to “solve all diseases” with AI.
Science podcast: Can gender diversity create better medicine?
This content was published on
In episode 3 of this season’s Swiss Connection science podcast we look at the role of sex and gender in drug development.
US trade deal forces reckoning for Swiss pharma powerhouse
This content was published on
Swiss pharma made massive investment promises to the US that are fueling anxiety about the industry’s future in Switzerland.
Under-50s cancer patients face system unprepared for them
This content was published on
Countries, including Switzerland, are struggling to deal with the challenges posed by rising cancer rates among people under 50.
This content was published on
Despite success with injectable drugs pharma companies are investing heavily in tablets, long considered the holy grail of obesity medicine.
How Switzerland became liberal on abortion – without noticing
This content was published on
From 2027 Swiss health insurers will cover the full cost of abortions. The change passed through parliament almost unnoticed.
Swiss drugmakers face mixed fortunes amid Trump’s tariff upheaval
This content was published on
Pharma giants may escape the worst of the import tariffs threatened by the US. But Switzerland’s smaller developers face a more uncertain future.
How private equity oversees the ethics of drug research
This content was published on
Many drug trials are vetted by companies with ties to the drugmakers, raising concerns about conflicts of interest and patient safety.
How a clash with Roche exposed cracks in Swiss drug pricing system
This content was published on
Switzerland’s new process to speed up patient access to the latest drugs hit its first major hurdle in a clash with Roche.
This content was published on
Ypsomed CEO explains why US tariffs are not a worry and why he sees more growth from diabetes and obesity treatments such as Ozempic.
When diagnosing a disease does more harm than good
This content was published on
Switzerland has the highest number of MRI scanners per person in Europe. But more screening doesn’t always lead to better health outcomes.
